Full-year report on Innate Pharma’s liquidity contract with Gilbert Dupont
First Phase II trial with IPH2201 open in head and neck cancer
Enrollment closed to new patients in the Phase I trial investigating lirilumab in combination with ipilimumab
ASH 2014 : Lirilumab enhances Elotuzumab activity in preclinical models
Innate Pharma announces its financial calendar for 2015 as well as its participation in upcoming investor conferences
Financial information for the third quarter of 2014
IPH 4102 preclinical data published in “cancer research”
Innate Pharma presents two posters on proprietary BTG-ADC technology at the world ADC Summit
Initiation of a Phase I clinical trial of lirilumab in combination with elotuzumab
Third data and safety monitoring board meeting for EffiKIR trial recommends continuation as planned
